Adding venetoclax to oral decitabine-cedazuridine improves responses in higher-risk MDS and CMML patients. Inqovi, an oral decitabine-cedazuridine combination, was FDA approved in 2020 for primary or ...
Shorter-duration venetoclax may be as effective as longer-duration treatment in AML and MDS, with no significant impact on overall survival. The study included 53 patients, predominantly male, with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback